Revolution Medicines Advances Zoldonrasib to Phase 3 After Strong Pancreatic Cancer Trial Results

Dow Jones07-02

Revolution Medicines reported early trial results showed that its experimental drug zoldonrasib produced strong antitumor activity in two combination regimens for patients with metastatic pancreatic cancer.

The late-stage clinical oncology company said Thursday that its drug zoldonrasib showed manageable safety profiles and high response rates in two different treatment approaches.

The company said the drug was tested with standard chemotherapy in previously untreated patients and in a doublet regimen with its RAS$(ON)$ inhibitor daraxonrasib in previously treated patients.

Pancreatic cancer is one of the most lethal forms of cancer, often discovered in later stages of development and many cases are often resistant to standard chemotherapy.

Revolution Medicines is advancing the ongoing RASolute 305 trial testing zoldonrasib in combination with standard chemotherapy and is planning the RASolute 309 trial evaluating the combination of zoldonrasib and daraxonrasib.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

July 02, 2026 08:40 ET (12:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648500388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648500388","market":"sh","top_or_hot":-1,"title":"Revolution Medicines Advances Zoldonrasib to Phase 3 After Strong Pancreatic Cancer Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> reported early trial results showed that its experimental drug zoldonrasib produced strong antitumor activity in two combination regimens for patients with metastatic pancreatic cancer. \n</p>\n<p>\n  The late-stage clinical oncology company said Thursday that its drug zoldonrasib showed manageable safety profiles and high response rates in two different treatment approaches. \n</p>\n<p>\n  The company said the drug was tested with standard chemotherapy in previously untreated patients and in a doublet regimen with its RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> inhibitor daraxonrasib in previously treated patients. \n</p>\n<p>\n  Pancreatic cancer is one of the most lethal forms of cancer, often discovered in later stages of development and many cases are often resistant to standard chemotherapy. \n</p>\n<p>\n  Revolution Medicines is advancing the ongoing RASolute 305 trial testing zoldonrasib in combination with standard chemotherapy and is planning the RASolute 309 trial evaluating the combination of zoldonrasib and daraxonrasib. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 02, 2026 08:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines Advances Zoldonrasib to Phase 3 After Strong Pancreatic Cancer Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines Advances Zoldonrasib to Phase 3 After Strong Pancreatic Cancer Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-02 20:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> reported early trial results showed that its experimental drug zoldonrasib produced strong antitumor activity in two combination regimens for patients with metastatic pancreatic cancer. \n</p>\n<p>\n  The late-stage clinical oncology company said Thursday that its drug zoldonrasib showed manageable safety profiles and high response rates in two different treatment approaches. \n</p>\n<p>\n  The company said the drug was tested with standard chemotherapy in previously untreated patients and in a doublet regimen with its RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> inhibitor daraxonrasib in previously treated patients. \n</p>\n<p>\n  Pancreatic cancer is one of the most lethal forms of cancer, often discovered in later stages of development and many cases are often resistant to standard chemotherapy. \n</p>\n<p>\n  Revolution Medicines is advancing the ongoing RASolute 305 trial testing zoldonrasib in combination with standard chemotherapy and is planning the RASolute 309 trial evaluating the combination of zoldonrasib and daraxonrasib. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 02, 2026 08:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2648500388","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648500388","pubTimestamp":1782996000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Revolution Medicines reported early trial results showed that its experimental drug zoldonrasib produced strong antitumor activity in two combination regimens for patients with metastatic pancreatic c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00BZ199S13.USD":"BNY MELLON MOBILITY INNOVATION \"B\" (USD) ACC","RVMD":"Revolution Medicines, Inc.","LU1861214812.USD":"Blackrock Future of Transport A2 USD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4139":"生物科技","LU2360107325.USD":"BGF FUTURE OF TRANSPORT \"A4\" (USD) INC","LU0124384867.USD":"贝莱德新能源基金A2","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","BK4588":"碎股","LU2298322129.HKD":"BGF SUSTAINABLE ENERGY \"A2\" (HKDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4605":"半导体精选","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0724618433.USD":"BGF NEW ENERGY \"A4\" (USD) INC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","ON":"安森美半导体","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","BK4512":"苹果概念","LU1548497426.USD":"安联环球人工智能AT Acc","BK4585":"ETF&股票定投概念","BK4141":"半导体产品","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"Revolution Medicines在胰腺癌试验结果强劲后将Zoldonrasib推进至3期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ON":1,"RVMD":1.5},"content_text":"Revolution Medicines reported early trial results showed that its experimental drug zoldonrasib produced strong antitumor activity in two combination regimens for patients with metastatic pancreatic cancer. \n\n\n  The late-stage clinical oncology company said Thursday that its drug zoldonrasib showed manageable safety profiles and high response rates in two different treatment approaches. \n\n\n  The company said the drug was tested with standard chemotherapy in previously untreated patients and in a doublet regimen with its RAS$(ON)$ inhibitor daraxonrasib in previously treated patients. \n\n\n  Pancreatic cancer is one of the most lethal forms of cancer, often discovered in later stages of development and many cases are often resistant to standard chemotherapy. \n\n\n  Revolution Medicines is advancing the ongoing RASolute 305 trial testing zoldonrasib in combination with standard chemotherapy and is planning the RASolute 309 trial evaluating the combination of zoldonrasib and daraxonrasib. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 02, 2026 08:40 ET (12:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648500388","isCrawlerRequest":true}